Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.39 |
| ▸ | FEN1 | P39748 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20117671 | 0.92 | SCN9A (0.39) | ALOX5APFEN1SCN9ACNR2 | |
| SCHEMBL20111515 | 0.91 | ALOX5AP (0.36) | ALOX5APFEN1SCN9ASCN5AOPRL1 | |
| SCHEMBL20102565 | 0.91 | ALOX5AP (0.33) | ALOX5APFEN1SCN9ACNR2 | |
| SCHEMBL20111289 | 0.90 | SLC6A4 (0.35) | ALOX5APFEN1 | |
| SCHEMBL20102395 | 0.89 | MEN1 (0.33) | ALOX5APFEN1OPRL1 | |
| SCHEMBL20111342 | 0.86 | ALOX5AP (0.39) | ALOX5APFEN1SCN9ASCN5A | |
| SCHEMBL20102611 | 0.85 | ALOX5AP (0.32) | ALOX5APFEN1SCN9ACNR2 | |
| SCHEMBL20117669 | 0.85 | SCN9A (0.43) | ALOX5APFEN1SCN9ASCN5ACNR2 | |
| SCHEMBL20102392 | 0.85 | HTR2A (0.34) | — | |
| SCHEMBL20111308 | 0.85 | ALDH1A1 (0.36) | ALOX5APFEN1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2019-06-18 | — | — | US | disclosed |
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119009-A1 | LIQUID CRYSTAL COMPOUND HAVING BIPHENYLENE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX1, PIEZO1, C1S | ALOX5AP 2002/4885FEN1 1547/4885SCN9A 2846/4885 |
| US-10323187-B2 | Liquid crystal compound having biphenylene, liquid crystal composition and liquid crystal display device | YBX1, PIEZO1, C1S | ALOX5AP 2002/4885FEN1 1547/4885SCN9A 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.